Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNDX-5613 phase 2 study in relapsed/refractory acute leukemias with KMT2A rearrangement or NPM1 mutation
NL-OMON56180Phase 2Recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of revumenib in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL) (3 arms), sponsored by Syndax Pharmaceuticals. Primary endpoints: CR+CRh rate, Safety and tolerability and 2 more. Started Dec 2022; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NL-OMON56180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56180.